Nancy Brown
Showing 1–8 of 8 transcripts.
- Milken Institute54 min
The Next Era of Health | Global Conference 2026
Esther Krofah, Robert Bradway, Nancy Brown, Alicia Jackson, Myechia Minter-Jordan, Dipen Parekh
Addressing a critical demographic tipping point and a $1 trillion caregiver gap, stakeholders including AARP, ARPA-H, and the American Heart Association are reforming U.S. healthcare to bridge the divide between technological innovation and clinical delivery. Initiatives range from deploying agentic AI to extend cardiovascular prevention to counties lacking specialists, to accelerating long-term care research through new regulatory pathways and a target reduction of drug discovery timelines to under five years. Concurrently, global competition drives a strategic pivot toward genomic integration and value-based models, with specific commitments to reduce Lipoprotein(a) levels by 95% and establish federal tax credits for the nation's 63 million caregivers.
- Milken Institute1h 0m
Championing Innovation and ROI in Women's Health Care | Global Conference 2024
Sheryl WuDunn, Nancy Brown, Jocelyn Frye, Kate Ryder, Maria Toler, Olivia Walton
Recent policy shifts and private investments have targeted critical gaps in women's health, following a White House initiative to fund research and a SteelSky-led advocacy push for $12 billion in congressional approval. Despite these efforts, severe disparities persist, including an 18% higher out-of-pocket cost for women, a 20% maternal mortality gap for Black women, and a clinical trial landscape where women of color remain severely underrepresented. Industry leaders and investors are now pivoting toward personalized, lifecycle-focused solutions and "Food is Medicine" models to address systemic barriers while capitalizing on the economic imperative of supporting female health.
- Milken Institute58 min
Poised to Break the Bank: Paying for Chronic Disease
Allison Aubrey, Nancy Brown, Thomas Davis, Anand Parekh, Eric, Michael Golinkoff, John Rother, Megan Golden, Jess Leifer, Stephanie Cousins
Geisinger Health's pilot food pharmacy program demonstrated that high-intensity nutritional support significantly lowers chronic disease costs and improves patient outcomes, prompting federal interest through the 2018 Farm Bill despite scalability challenges. While experts advocate for integrated payment models and preventive policies like sugar taxes to address widespread chronic conditions, systemic barriers including data fragmentation, misaligned pharmaceutical incentives, and insufficient medical education continue to hinder broad adoption. Successful scaling now requires multi-payer collaboration to align financial incentives and address interconnected mental health and pain management needs that frequently undermine lifestyle interventions.
- Milken Institute55 min
The Promise of Public Health
Mike Klowden, Richard Besser, Nancy Brown, Thomas Farley, Joseph Jimenez, Fred Upton
The Milken Institute's inaugural Public Health Summit convened key industry and government leaders, including Novartis CEO Joe Jimenez, CDC Director Tom Frieden, and Congressman Fred Upton, to advocate for elevating disease prevention alongside medical cures. Participants analyzed critical strategies such as conditional reimbursement models, real-time data utilization, and the "21st Century Cures Act" to address looming challenges posed by an aging global population and stagnant biotech venture capital. The consensus emphasized that sustainable health outcomes require shifting from volume-based treatment to outcome-based policies that integrate genomics, behavioral interventions, and bipartisan legislative support to bridge significant disparities in US public health metrics.
- Milken Institute47 min
The Economic Impact of Chronic Disease
Ross DeVol, Nancy Brown, Neal Kaufman, Kristen Miranda, Hugh Waters, Otis Webb Brawley
The Milken Institute convened health leaders and researchers to address the escalating economic and human toll of chronic diseases, emphasizing that 80% of cardiovascular conditions and rising cancer rates are preventable through lifestyle changes and systemic reform. Speakers highlighted stark disparities linked to education and income while detailing how policy interventions, such as Medicaid expansion and Accountable Care Organizations, can reduce waste and improve early detection. The session concluded with a unified call to shift from fee-for-service models to patient-centric strategies that leverage digital tools and early education to extend healthy life years rather than merely treating illness.
- Milken Institute1h 1m
The Business Case for Wellness: Is a Wellness Dollar Worth More than a Treatment Dollar?
Linda Fried, Nancy Brown, Bill Dietz, Steve Bird, Andy
A multi-sector panel of healthcare leaders and corporate executives argues that shifting resources from treatment to prevention is now a viable, high-ROI business model capable of reducing US healthcare costs by 40–50%. Successful implementation relies on collaborative strategies between governments, corporations like Safeway, and individuals to address environmental drivers of disease while leveraging technology for personal accountability. Despite persistent socioeconomic disparities and small business constraints, experts agree that aligning financial incentives across payers and providers will create a necessary "culture of health" to reverse the US health paradox within the next decade.
- Milken Institute1h 11m
Lunch Panel: A Cure for What Ails Us: Celebrating the Impact of Science (updated II)
Nancy Brown, Francis Collins, Thomas Frieden, Andrew von Eschenbach, Michael Milken, Mike Milken, Tom Frieden, Andy Van Eschenbach, Jack Andreyka
A comprehensive analysis of global bioscience reveals a dramatic increase in life expectancy and major breakthroughs in disease eradication, such as the near-elimination of polio and HIV management through programs like PEPFAR. Despite these successes, the sector faces a critical funding crisis where declining NIH grant success rates and inflation-adjusted budget cuts threaten the pipeline of young researchers and the translation of genetic discoveries into new treatments. Strategic initiatives like the Brain Initiative, precision medicine efforts, and the shift toward prevention are now essential to address rising chronic disease burdens and sustain the bioscience industry as a primary driver of US economic growth.
- Milken Institute1h 12m
Lunch Panel: A Cure for What Ails Us: Celebrating the Impact of Science
Nancy Brown, Francis Collins, Thomas Frieden, Andrew von Eschenbach, Michael Milken
The bioscience forum highlighted the sector's massive contribution to increased global life expectancy and economic growth while emphasizing that flat budgets and inflation have critically reduced NIH grant success rates to below 20%. Distinguished leaders such as Francis Collins and Tom Frieden warned that sustained funding cuts and a 90% treatment-versus-prevention spending imbalance threaten American innovation and the careers of young researchers. Despite these financial constraints, the event underscored significant breakthroughs in areas like genomic medicine and disease eradication, with panelists urging renewed investment to maintain global health leadership and drive future discoveries.